4827 T3D4772 Stavudine A dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV. 3056-17-5 18283 C10H12N2O4 White powder. 159-160°C 5-10 g/100 mL at 21°C Following oral administration, stavudine is rapidly absorbed (bioavailability is 68-104%). Stavudine inhibits the activity of HIV-1 reverse transcriptase (RT) both by competing with the natural substrate dGTP and by its incorporation into viral DNA. Phosphorylated intracellularly to stavudine triphosphate, the active substrate for HIV-reverse transcriptase. Half Life: 0.8-1.5 hours (in adults) No indication of carcinogenicity to humans (not listed by IARC). For the treatment of human immunovirus (HIV) infections. Side effects include peripheral neuropathy tingling, burning, numbness, or pain in the hands or feet), fatal lactic acidosis has been reported in patients treated with stavudine (ZERIT) in combination with other antiretroviral agents, severe liver enlargement, inflammation (pain and swelling) of the liver, and liver failure. 2014-09-11T05:15:56Z 2014-12-24T20:26:57Z Stavudine C07312 63581 DB00649 true [H][C@]1(CO)O[C@]([H])(C=C1)N1C=C(C)C(O)=NC1=O C10H12N2O4 InChI=1S/C10H12N2O4/c1-6-4-12(10(15)11-9(6)14)8-3-2-7(5-13)16-8/h2-4,7-8,13H,5H2,1H3,(H,11,14,15)/t7-,8+/m0/s1 InChIKey=XNKLLVCARDGLGL-JGVFFNPUSA-N 224.2133 224.079706882 Exogenous Solid -0.72 HMDB14787 CHEMBL991 17270 <p>Purna Chandra Ray, Jagan Mohana Chary Tummanapalli, Seeta Ramanjaneyulu Gorantla, &#8220;Process for the Large Scale Production of Stavudine.&#8221; U.S. Patent US20080312428, issued December 18, 2008.</p>